Cannabis use in adolescents and anxiety symptoms and disorders: a systematic review and meta-analysis

ABSTRACT

Background: The use of cannabis is highly prevalent during adolescence compared to the general adult population. In addition to the high comorbidity between cannabis use and anxiety disorders, early evidence suggests that cannabis may precede the development of anxiety. Moreover, adolescence represents a major developmental period for both neurobiological and psychological processes, placing these individuals at a heightened vulnerability to the influence of cannabis.

Objectives: This systematic review and meta-analysis examined the prospective associations between adolescent cannabis use and subsequent anxiety outcomes (i.e. anxiety disorders and/or symptoms).

Methods: Following PRISMA guidelines, a systematic review and meta-analysis were conducted encompassing data from articles published between database inception and September 2022.

Results: Six longitudinal studies were identified for quantitative analysis, while twelve non-overlapping longitudinal studies were identified for qualitative review (total N = 18; 33380 subjects). Meta-analytical findings supported an association between adolescent cannabis use and the development of a subsequent anxiety disorder (Odds Ratio = 2.14, 95% CI: 1.37–3.36, p < .01). These findings were consistent with our qualitative synthesis where nine of the twelve longitudinal studies observed a significant relationship between adolescent cannabis use and exacerbation of anxiety symptoms later in life, irrespective of an anxiety disorder diagnosis.

Discussion: In summary, the current evidence suggests a prospective association between adolescent cannabis use and later anxiety symptoms and disorders. These findings underscore the importance of refining research methodologies, considering sex-based differences and controlling for confounding factors, as well as implementing educational initiatives and developing clinical interventions to address the mental health risks associated with cannabis use among adolescents.

KEYWORDS:

• Adolescents
• anxiety disorders
• cannabis
• child development

Disclosure statement

MS and DL have no competing interests. Dr. George has received consulting fees from Roche, Frutarom, Aelis and Sanford Burnham Prebys. He also serves as Co-Principal Editor, Neuropsychopharmacology (NPP).

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/00952990.2023.2299922

Additional information

Funding

This study was supported in part by NIDA grant R21-DA-043949, CIHR [PJT-190053] and the CAMH Foundation [to Dr. George].